Based on these findings, co-targeting p53 mutation and its associated pathways activated by docetaxel may improve the therapeutic effectiveness of current anti-PCa drugs and delay docetaxel resistance in PCa. The gene discussed is TP53; the disease is posterior cortical atrophy.